• Explore /
  • Poster
  • / Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating <em>FGFR1/2/3</em> genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.

Abstract Poster

Authors

Andrea Necchi

Andrea Necchi

Vita-Salute San Raffaele University; Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy

Andrea Necchi , Tilman Todenhöfer , Jean-Laurent Deville , Manuel Häckl , Michalina Marszewska , Phil McKernan , Mikael Saulay , Marc Engelhardt , Maria De Santis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04045613

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 501)

DOI

10.1200/JCO.2023.41.6_suppl.501

Abstract #

501

Poster Bd #

K5

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).

Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).

First Author: Fuxiang Zhou

First Author: Sébastien Perreault

First Author: Michal Sternschuss

First Author: Jin-Ji Yang